---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033356"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T11:20:47.115632+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals enters consulting & amended services agreements with related party Epiq Scripts

## Summary
- Engaged Epiq Scripts for global pharmacy consulting outside US; $65K upfront plus per-pill declining fees over 5 years (amounts redacted).
- Amended MSA: added right of first negotiation/refusal for new jurisdictions and a 1% non-use fee on gross sales if services transferred.
- Epiq Scripts is 51% owned by CEO Jacob D. Cohen; the agreements are related-party transactions.
- No consulting payments until first commercial sale outside US; no immediate revenue impact expected.

## SEC filing metadata
- accession: 0001493152-23-033356
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033356
- JSON: https://secwatch.observer/filing/0001493152-23-033356.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033356.txt

## Key facts
- Material Agreements
  MANGOCEUTICALS, INC. entered into Consulting Agreement with Epiq Scripts, LLC (effective 2023-09-15).
  - Action: entry
  - Counterparty: Epiq Scripts, LLC
  - Effective: 2023-09-15
  source text: On September 15, 2023, Mangoceuticals, Inc. (the " Company ", " we " and " us ") entered into (1) a Consulting Agreement (the " Consulting Agreement ") with Epiq Scripts, LLC (" Epiq Scripts ")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm
- Material Agreements
  MANGOCEUTICALS, INC. amended First Addendum to Master Services Agreement with Epiq Scripts, LLC (effective 2023-09-15).
  - Action: amendment
  - Counterparty: Epiq Scripts, LLC
  - Effective: 2023-09-15
  source text: and (2) a First Addendum to Master Services Agreement with Epiq Scripts (the " First Amendment "), which amended that certain Master Services Agreement dated September 1, 2022, by and between the Company and Epiq Scripts (the " MSA ")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.